Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5968
    +0.0018 (+0.31%)
     
  • NZD/EUR

    0.5549
    +0.0009 (+0.17%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    83.82
    +0.25 (+0.30%)
     
  • GOLD

    2,357.60
    +15.10 (+0.64%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,113.11
    +34.25 (+0.42%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    18,048.65
    +131.37 (+0.73%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    93.2990
    +0.8030 (+0.87%)
     

Roche Takes Drug-Price Posturing to New Heights

Roche Takes Drug-Price Posturing to New Heights

Pfizer Inc. started things off earlier this month by agreeing to roll back mid-year price hikes and delay them — for a few months. Similar efforts announced this week by Novartis AG and Merck & Co. arguably won’t be any more consequential. In a statement Friday, the Swiss pharmaceutical giant said it told the Health and Human Services Department on July 11 that it wouldn’t enact any more price hikes in 2018.